自拟益气健脾汤加减治疗肺脾气虚型中晚期非小细胞肺癌的效果  

Efficacy of Self-Formulated Yiqi Jianpi Decoction with Modifications in Treating Intermediate to Advanced Stage Non-Small Cell Lung Carcinoma with Lung and Spleen Qi Deficiency Syndrome

作　　者：钱玉红 刘凌齐 李延芳 QIAN Yu-hong;LIU Ling-qi;LI Yan-fang(Department of Hematology and Oncology,Shangqiu Hospital of Traditional Chinese Medicine,Shangqiu 476000,China)

机构地区：[1]商丘市中医院肿瘤血液科,商丘476000

出　　处：《中国合理用药探索》2025年第2期111-117,共7页Chinese Journal of Rational Drug Use

摘　　要：目的:探讨自拟益气健脾汤加减治疗对肺脾气虚型中晚期非小细胞肺癌(NSCLC)的效果。方法:选取2022年10月1日~2024年3月31日期间于某院收治的80例肺脾气虚型中晚期NSCLC患者作为研究对象,采用随机数字表法分为对照组和观察组,每组40例。对照组患者给予GP方案(注射用盐酸吉西他滨、注射用顺铂)治疗,观察组患者在对照组化疗基础上给予自拟益气健脾汤加减治疗。比较两组免疫功能(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、炎症因子[白介素-2(IL-2)、白介素-12(IL-12)、肿瘤坏死因子-α(TNF-α)]、肿瘤标志物[谷胱甘肽S-转移酶P1(GSTP1)、糖类抗原125(CA125)、癌胚抗原(CEA)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]、Janus激酶2(JAK2)/信号转导和转录激活因子3(STAT3)信号通路相关指标(JAK2 mRNA、STAT3 mRNA)、中医症状评分、临床疗效及不良反应发生情况。结果:治疗后,观察组患者CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)高于对照组(P<0.05),CD8^(+)低于对照组(P<0.05)。两组患者IL-2、IL-12、TNF-α、GSTP1、CA125、CEA、CYFRA21-1、JAK2 mRNA、STAT3 mRNA以及中医症状评分均降低(P<0.05),且观察组低于对照组(P<0.05)。观察组患者客观缓解率(62.50%)高于对照组(40.00%,P<0.05)。两组患者不良反应总发生率比较无统计学差异(P>0.05)。结论:自拟益气健脾汤加减治疗可提高肺脾气虚型中晚期NSCLC患者的临床疗效,抑制炎症因子,降低肿瘤标志物水平及减轻免疫抑制。Objective:To investigate the efficacy of self-formulated Yiqi Jianpi decoction with modifications in treating intermediate to advanced stage non-small cell lung carcinoma(NSCLC)with lung and spleen Qi deficiency syndrome.Methods:A total of 80 intermediate to advanced stage NSCLC patients with lung and spleen Qi deficiency syndrome treated in a hospital from October 1,2022 to March 31,2024 were selected and assigned to the control group and observation group by random number table method,with 40 patients in each group.The control group was given GP scheme(gemcitabine hydrochloride for injection,cisplatin for injection),and the observation group was given self-formulated Yiqi Jianpi decoction with modifications in addition to the chemotherapy given in the control group.The immune function(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),inflammatory factors[interleukin-2(IL-2),interleukin-12(IL-12),tumor necrosis factor-α(TNF-α)],tumor markers[glutathione S-transferase P1(GSTP1),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)],Janus kinase 2(JAK2)/signal transducer and activator of transcription 3(STAT3)signaling pathway related indicators(JAK2 mRNA,STAT3 mRNA),traditional Chinese medicine(TCM)symptom score,clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group(P<0.05),while CD8^(+)in the observation group was lower than that in the control group(P<0.05).The levels of IL-2,IL-12,TNF-α,GSTP1,CA125,CEA,CYFRA21-1,JAK2 mRNA,STAT3 mRNA and TCM symptom scores were decreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).The objective remission rate in the observation group(62.50%)was higher than that in the control group(40.00%,P<0.05).No statistically significant difference was observed in the total incidence of adverse reactions between the two groups(P>0.05).Con

关 键 词：益气健脾汤 肺脾气虚型 非小细胞肺癌 炎症因子 肿瘤标志物 疗效 

分 类 号：R734.2[医药卫生—肿瘤]